TICKERNERD
Menu
GRALGRALHealthcare · Diagnostics & Research

GRAL Stock Forecast: GRAIL, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$68
−0.54% on the day

The 9 Wall Street analysts covering GRAIL, Inc. hold a median 12-month price target of $75 — +9.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 36 of 100 as at 15 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$3.0B
Ticker Nerd rank
36 / 100
Median analyst target
$75
Analysts covering
9
Total return, dividends reinvested
1W
−2.3%
1M
−7.2%
YTD
−20.7%
1Y
+110.9%
From 52W high
−41.5%
From 52W low
+116.0%
$31
$116
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

GRAL stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores GRAIL, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
36 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
81
Momentum
69
Accruals
59
Growth
53
Size
31
Quality
27
Value
26
Issuance
23
Volatility
12

Revisions (81): Analysts have, on balance, been raising their forecasts.

Volatility (12): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

GRAL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on GRAL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$40$60$80$100$120Oct 25Jan 26Apr 26Jul 26GRALHigh $88Median $75Low $60

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says9 analysts
4 Buy5 Hold0 Sell
Low $60Median $75High $88

The green dot is the last close — the median target sits +9.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
15 July 2026MizuhoMaintainsNeutral$58 → $65
5 June 2026Goldman SachsInitiatesNeutral$60
5 June 2026Goldman SachsInitiatesNeutral—
6 May 2026Piper SandlerMaintainsNeutral—
6 May 2026TD CowenMaintainsBuy—
10 Apr 2026MizuhoInitiatesNeutral—
10 Apr 2026Piper SandlerInitiatesNeutral—
30 Mar 2026GuggenheimMaintainsBuy—
24 Feb 2026Morgan StanleyMaintainsEqual-Weight—
20 Feb 2026BairdMaintainsOutperform—
20 Feb 2026Canaccord GenuityMaintainsBuy—
17 Feb 2026BairdInitiatesOutperform—
26 Jan 2026GuggenheimMaintainsBuy—
2 Dec 2025Morgan StanleyMaintainsEqual-Weight—
17 Nov 2025Canaccord GenuityMaintainsBuy—
12 Nov 2025GuggenheimUpgradeBuy—
22 Oct 2025Canaccord GenuityMaintainsBuy—
3 Oct 2025Canaccord GenuityMaintainsBuy—
14 May 2025Canaccord GenuityMaintainsBuy—
21 Apr 2025Canaccord GenuityInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. GRAL appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

GRAL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

GRAIL, Inc. (GRAL) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−6.1×

Cheaper than 91% of US stocks

Price / sales
18.3×

Cheaper than 10% of US stocks

Price / book
1.1×

Cheaper than 71% of US stocks

EV / EBITDA
−6.0×

Cheaper than 80% of US stocks

Growth & margins
Revenue growth (YoY)
25.7%

Higher than 75% of US stocks

Earnings growth (YoY)
25.7%

Higher than 64% of US stocks

Gross margin
−28.1%

Higher than 3% of US stocks

Operating margin
−332.0%

Higher than 9% of US stocks

Net margin
−236.9%

Higher than 2% of US stocks

Returns & dividend
Return on equity
−16.1%

Higher than 32% of US stocks

Return on assets
−12.0%

Higher than 25% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

GRAL vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
GRALGRAIL, Inc.$3.0B
36
VCYTVeracyte, Inc.$3.3B
97
CDNACareDx, Inc.$2.3B
100
ADPTAdaptive Biotechnologies Corp.$4.0B
78
WGSGeneDx Holdings Corp.$2.2B
47
BLLNBillionToOne, Inc.$4.4B
15
NEONeoGenomics, Inc.$2.0B
76

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own GRAIL, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest GRAL news & analysis

GRAIL Highlights Galleri Growth Ahead of Key FDA Advisory Meeting

MarketBeat · 14 Aug 2026positive

GRAIL Chief Financial Officer Aaron Freidin said the company's Galleri multi-cancer early detection test saw strong first-half growth as it expanded distribution through digital health platforms, employers, and physician offices. The comments come ahead of a key FDA advisory meeting on the test.

Why it matters — A GRAL watcher would care because strong Galleri growth and expanded distribution suggest momentum ahead of a significant regulatory milestone for the company's core product.

GRAIL: Looking Beyond The NHS-Galleri Headline

Seeking Alpha · 12 Aug 2026negative

GRAIL faces a binary FDA approval decision for its Galleri test that is expected to drive significant stock movement. The piece notes disappointing NHS-Galleri trial results, argues the test's value may have shown with a longer monitoring period, and warns that commercialization delays could force the company to raise capital on unfavorable terms despite a solid cash position.

Why it matters — A GRAL watcher would care because this update outlines both a pivotal upcoming FDA catalyst for Galleri and a notable risk of dilutive capital raising amid commercialization delays.

FDA Panel Schedules to Evaluate GRAIL Premarket Approval Application for Multi-Cancer Early Detection Test

Benzinga · 10 Aug 2026neutral

GRAIL Inc. announced that the FDA's Molecular and Clinical Genetics Panel is preparing to evaluate the company's premarket approval application for its flagship multi-cancer early detection test. The regulatory review represents a pivotal upcoming event for the healthcare company.

Why it matters — The FDA panel's evaluation of GRAIL's multi-cancer early detection test is a key regulatory milestone that could determine the path to market approval for its flagship diagnostic tool.

US FDA to hold advisory meeting to review Grail's multi-cancer test

Reuters · 7 Aug 2026positive

GRAIL said on Friday that the U.S. FDA plans to hold a meeting of outside experts in September to review its multi-cancer screening test, Galleri, which lifted the company's shares 4% in morning trade.

Why it matters — An FDA advisory committee review is a key regulatory step for Galleri, so a GRAL watcher would follow this meeting closely as it progresses toward potential regulatory clearance.

GRAIL Announces FDA Advisory Committee Meeting to Review Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test

PRNewsWire · 7 Aug 2026neutral

GRAIL announced that the FDA's Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is scheduled to meet in September to review the company's Premarket Approval application for its Galleri multi-cancer early detection test.

Why it matters — The FDA advisory committee review is a key regulatory step toward potential approval of GRAIL's Galleri test, a core product in its pipeline.

FAQ

Frequently asked questions about GRAL stock

What is the GRAL stock price forecast for 2026-2027?

The 9 Wall Street analysts covering GRAIL, Inc. have a median 12-month price target of $75, with estimates ranging from $60 to $88. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is GRAL stock a buy right now?

Of the 9 analysts covering GRAIL, Inc., 4 rate it a Buy, 5 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks GRAIL, Inc. 36 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank GRAL?

As at 15 Aug 2026, GRAIL, Inc. ranks 36 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (81 of 100).

Will GRAL stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +9.8% from the last close, and Ticker Nerd's factor model ranks GRAIL, Inc. 36 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the GRAL stock forecast for 2030?

No analyst covering GRAIL, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GRAL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $60 to $88 over the next 12 months.

How has GRAL stock performed over the past year?

GRAIL, Inc. returned +110.9% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does GRAIL, Inc. do?

GRAIL, Inc. is a healthcare biotechnology company focused on early cancer detection.

What is the latest news on GRAL?

The most recent item we track (MarketBeat, 14 Aug 2026): "GRAIL Highlights Galleri Growth Ahead of Key FDA Advisory Meeting". GRAIL Chief Financial Officer Aaron Freidin said the company's Galleri multi-cancer early detection test saw strong first-half growth as it expanded distribution through digital health platforms, employers, and physician offices. The comments come ahead of a key FDA advisory meeting on the test.

Company

About GRAIL, Inc.

GRAIL, Inc. is a healthcare biotechnology company focused on early cancer detection. The company develops and commercializes blood-based screening products designed to identify signals from multiple cancer types before symptoms appear, supporting earlier clinical follow-up and diagnosis. Its primary offering, Galleri, is used in multi-cancer early detection and complements standard guideline-recommended screenings. GRAIL also applies genomics, machine learning, and large-scale clinical data to advance precision oncology applications such as risk stratification, minimal residual disease detection, biomarker subtyping, and recurrence monitoring. Headquartered in Menlo Park, California, GRAIL serves healthcare providers, health systems, and patients in the United States and internationally through its commercial-stage diagnostics business.

CEO Dr. Joshua J. Ofman M.D., M.S.H.S · 910 employees · United States · https://grail.com